At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
eribulin mesylatedrug
Likely dose
eribulin mesylate 1.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma
In Brief
A Phase 2 clinical trial evaluating eribulin mesylate for Soft Tissue Sarcoma. Completed, enrolled 52 participants across 12 sites.
Detailed Summary
The purpose of the study is to evaluate the efficacy and safety of eribulin mesylate in subjects with soft tissue sarcoma who received at least one standard chemotherapy (an anthracycline or an ifosfamide monotherapy or a combination therapy).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartNov 2011
Primary CompletionNov 2014
Study CompletionFeb 2016
TodayJul 2026
First PostedOct 24, 2011
Enrollment StartNov 1, 2011
Primary CompletionNov 1, 2014
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 14.7 years ago
Interventions
eribulin mesylatedrug
Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.